CN112138138A - A pharmaceutical composition for treating gout and preparation method thereof - Google Patents

A pharmaceutical composition for treating gout and preparation method thereof Download PDF

Info

Publication number
CN112138138A
CN112138138A CN202011300901.4A CN202011300901A CN112138138A CN 112138138 A CN112138138 A CN 112138138A CN 202011300901 A CN202011300901 A CN 202011300901A CN 112138138 A CN112138138 A CN 112138138A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
alanine
glucan
methionine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011300901.4A
Other languages
Chinese (zh)
Other versions
CN112138138B (en
Inventor
徐庆阳
李志华
熊海波
张宁
杨柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lekang Zhentai Tianjin Biotechnology Co ltd
Tianjin University of Science and Technology
Original Assignee
Lekang Zhentai Tianjin Biotechnology Co ltd
Tianjin University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lekang Zhentai Tianjin Biotechnology Co ltd, Tianjin University of Science and Technology filed Critical Lekang Zhentai Tianjin Biotechnology Co ltd
Priority to CN202011300901.4A priority Critical patent/CN112138138B/en
Publication of CN112138138A publication Critical patent/CN112138138A/en
Application granted granted Critical
Publication of CN112138138B publication Critical patent/CN112138138B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a pharmaceutical composition for treating gout and a preparation method thereof, wherein the pharmaceutical composition comprises the following effective components, by weight, 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of compound active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of micromolecular potassium hyaluronate, 5-10 parts of D-glucosamine ketone glutarate, 3-5 parts of glutamine, 2-5 parts of L-alanine, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C, and can be prepared by a mixing mode, and the pharmaceutical composition can effectively improve and treat metabolic arthritis such as gout and the like, rheumatic arthritis, and the like, Chronic diseases such as rheumatoid arthritis and the like, joint repair, joint pain reduction, muscle synthesis increase and uric acid metabolism acceleration.

Description

A pharmaceutical composition for treating gout and preparation method thereof
Technical Field
The invention relates to a gout treatment medicine and a preparation method thereof, in particular to a medicine composition for treating gout and a preparation method thereof.
Background
Gout is a group of heterogeneous chronic metabolic diseases caused by purine metabolic disorder, and is clinically characterized by hyperuricemia, recurrent gouty acute arthritis, interstitial nephritis and tophus formation; severe cases are accompanied by joint deformity or uric acid urinary calculus. The gout has the clinical characteristics that: hyperuricemia; recurrent attacks of gouty acute arthritis; tophus formation and deposition tophus-type diffuse arthritis; joint deformity, etc.
The ventilation forming process is mainly caused by the excessive accumulation of uric acid, and the main reasons for the accumulation of uric acid are as follows: when food with high purine content is excessively eaten, purine metabolism in the body is problematic, the excretion is too low, and uric acid cannot be normally excreted. According to the mechanism of uric acid production, reduction of uric acid production is necessary for preventing and treating gout, reduction of purine in vivo is necessary for reducing uric acid production, oxidative degradation of nucleic acid and purine intake are necessary for reducing purine in vivo, and elimination of uric acid is enhanced at the same time. At present, the medicines for treating gout in the market are more, such as colchicine, sunflower disc alkaloid, allopurinol, probenecid and the like, which are used for treating symptoms and root causes serious damage to liver and kidney functions, hemolytic anemia, anaphylactic shock and other side effects, some plant alkaloids can neutralize uric acid, and the pain of patients is aggravated.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating gout.
Another technical problem to be solved by the present invention is to provide a preparation method of the above pharmaceutical composition for treating gout.
The technical scheme adopted by the invention is as follows:
a pharmaceutical composition for treating gout comprises, by weight, 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of composite active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of small molecular potassium hyaluronate (molecular weight is less than 3000), 2-5 parts of D-glucosamine ketoglutarate, 2-5 parts of L-alanine, 2-5 parts of composite active alkaloid, and 3-15 parts of deep sea fish peptide, 2-5 parts of small molecular potassium hyaluronate (molecular weight is less than 3000), 3-10 parts of D-glucosamine ketoglutarate, 3-5 parts of glutamine and 2-5 parts of L-alanine, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C.
Preferably, the pharmaceutical composition for treating gout comprises, by weight, 26.5 parts of euglena beta-1, 3-glucan, 29.4 parts of composite active alkaloid, 7.2 parts of deep sea fish peptide, 3.5 parts of small molecular potassium hyaluronate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, 3.5 parts of L-lysine, 6.0 parts of L-leucine and 0.5 part of vitamin C.
The pharmaceutical composition for treating gout can be prepared into powder, capsules or granules.
The preparation method of the pharmaceutical composition for treating gout comprises the following specific steps:
(1) weighing euglena beta-1, 3-glucan, composite active alkaloid, deep sea fish peptide, micromolecular potassium hyaluronate (the molecular weight is less than 3000), D-aminoglucosone glutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to the parts by weight;
(2) and (2) uniformly mixing the components in the step (1).
The invention has the beneficial effects that:
the pharmaceutical composition for treating gout can effectively improve and treat metabolic arthritis such as gout, chronic diseases such as rheumatic arthritis and rheumatoid arthritis, repair joints, reduce joint pain, increase muscle synthesis and accelerate uric acid metabolism.
Detailed Description
To further illustrate the present invention, reference is made to the following examples:
example 1
A pharmaceutical composition for treating gout comprises, as effective components, beta-1, 3-glucan of Euglena, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the beta-1, 3-glucan of Euglena is 26.5%, the compound active alkaloid is 29.4%, the deep sea fish peptide is 7.2%, the small molecular potassium hyaluronate is 3.5%, the D-glucosamine ketoglutarate is 8.6%, the glutamine is 4.1%, the L-alanine is 3.0%, the L-arginine is 4.2%, the L-methionine is 3.5%, the L-lysine is 3.5%, the L-leucine is 6.0%, 0.5 percent of vitamin C.
The medicinal composition for treating gout is prepared into powder (5 g/bag), and the preparation method comprises the following specific steps:
(1) weighing euglena beta-1, 3-glucan, composite active alkaloid, deep sea fish peptide, micromolecular potassium hyaluronate (the molecular weight is less than 3000), D-aminoglucosone glutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to the parts by weight;
(2) and (2) uniformly mixing the components in the step (1).
Example 2
A pharmaceutical composition for treating gout comprises, as effective components, beta-1, 3-glucan of Euglena, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the beta-1, 3-glucan of Euglena is 30%, the compound active alkaloid is 15%, the deep sea fish peptide is 15%, the small molecular potassium hyaluronate (molecular weight is less than 3000) is 5%, the D-glucosamine ketoglutarate is 5%, the glutamine is 5%, the L-alanine is 5%, the L-arginine is 3%, the L-methionine is 2%, the L-lysine is 3%, the L-leucine is 9%, 1% of vitamin C.
The preparation method is as in example 1.
Example 3
A pharmaceutical composition for treating gout comprises, as effective components, beta-1, 3-glucan of Euglena, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the beta-1, 3-glucan of Euglena is 18%, the compound active alkaloid is 35%, the deep sea fish peptide is 3%, the small molecular potassium hyaluronate (molecular weight is less than 3000) is 2%, the D-glucosamine ketoglutarate is 10%, the glutamine is 3%, the L-alanine is 2%, the L-arginine is 6%, the L-methionine is 5%, the L-lysine is 6%, the L-leucine is 5%, 0.2 percent of vitamin C.
The preparation method is as in example 1.
Example 4
A pharmaceutical composition for treating gout comprises, as effective components, beta-1, 3-glucan of Euglena, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the beta-1, 3-glucan of Euglena 23%, the compound active alkaloid 27%, the deep sea fish peptide 10%, the small molecular potassium hyaluronate (molecular weight is less than 3000) 4%, D-glucosamine ketoglutarate 8%, glutamine 4%, L-alanine 3%, L-arginine 5%, L-methionine 4%, L-lysine 4%, L-leucine 7%, 0.6 percent of vitamin C.
The preparation method is as in example 1.
And (3) composition analysis:
(1) the euglena glucan can reduce uric acid, reduce cholesterol and enhance resistance, the compound active alkaloid directly neutralizes uric acid, and glutamine, alanine, arginine (expanding blood vessels) and VC have the synergistic effects of protecting liver and nourishing kidney; fundamentally treating and ventilating by nourishing the liver and the kidney;
(2) the micromolecule nano-material is quickly absorbed, has no toxic or side effect, no hormone and no dependence;
(3) lysine and alanine have synergistic diuretic effect, are beneficial to discharge of uric acid, and can inhibit severe hypertension (hypertension accompanied by general ventilation) in cooperation with methionine;
(4) the micromolecular potassium hyaluronate and D-aminoglucosone glutarate have the effects of synergistically protecting joints, softening blood vessels and the like, reducing joint pain and repairing joints;
(5) vitamin C, diminishing inflammation, relieving pain, repairing kidney, reducing urea content in body, and promoting absorption of other four components.
The components have synergistic effect and remarkable effect of treating gout.
Experimental example 1
The pharmaceutical composition (5 g/bag) described in example 1 was administered 4 times a day and once every 6 hours, with 500 ML and 700ML purified water for each time. A course of treatment is 30 days after administration. The gout patients are tested in 50 cases, wherein 30 cases of middle-aged and young patients are 20-45 years old, the average age is 35.5 years old, the middle-aged and old patients are 46-76 years old, and the average age is 57.2 years old. The patients were all male, and all patients met the diagnostic criteria for gout. The average uric acid level of young patients is 523 +/-71.2 mu mol/L, and the average uric acid level of middle-aged and old patients is 565 +/-62.3 mu mol/L. The clinical attack frequency of young patients is 3.5 +/-0.6 times per year on average, and the average frequency of middle-aged and old patients is 3.8 +/-0.4 times per year on average.
50 patients with gout in the group had the main pathological changes, 23 cases with single arthritis and 34 cases with polyarthritis, and the main affected joints were the first toe joint 46 case, the ankle joint 16 case, the other metatarsophalangeal joints 11 case and the knee joint 9 case. 42 cases are completely relieved and 7 cases are improved after being treated by the medicine in the embodiment 1, and the clinical effective rate reaches 98.0 percent.
Experimental example 2
A group of 8 patients, the age of which is 43-61 years old, are all male, are selected for follow-up test, the uric acid values measured by venous blood of the 8 patients are all more than 550umol/L, the pharmaceutical composition (5 g/bag) described in application example 1 is taken for 4 times per day, the pharmaceutical composition is taken every 6 hours, and the drinking water is 500 ML of purified water for each time. Through observation, the uric acid content is detected to be reduced rapidly on the 5 th day, 6 patients recover to normal values when the uric acid content is detected for 30 days, and the uric acid content is completely recovered to normal through treatment for 60 days.
Figure DEST_PATH_IMAGE001
The above-mentioned embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements made to the technical solution of the present invention by those skilled in the art without departing from the spirit of the present invention shall fall within the protection scope defined by the claims of the present invention.

Claims (4)

1. A pharmaceutical composition for treating gout, comprising: the functional components comprise beta-1, 3-glucan of euglena, compound active alkaloid, deep sea fish peptide, micromolecule potassium hyaluronate with the molecular weight less than 3000, D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the euglena beta-1, 3-glucan is 18-30 parts, the compound active alkaloid is 15-35 parts, the deep sea fish peptide is 3-15 parts, the micromolecule potassium hyaluronate is 2-5 parts, the D-glucosamine ketoglutarate is 5-10 parts, the glutamine is 3-5 parts, the L-alanine is 2-5 parts, the L-arginine is 3-6 parts, the L-methionine is 2-5 parts, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C.
2. The pharmaceutical composition for the treatment of gout according to claim 1, wherein: 26.5 parts of euglena beta-1, 3-glucan, 29.4 parts of compound active alkaloid, 7.2 parts of deep sea fish peptide, 3.5 parts of micromolecular potassium hyaluronate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, 3.5 parts of L-lysine, 6.0 parts of L-leucine and 0.5 part of vitamin C.
3. The pharmaceutical composition for the treatment of gout according to claim 1, wherein: the medicine composition is powder, capsule or granule.
4. The process for preparing a pharmaceutical composition for treating gout according to claim 1, wherein: the method comprises the following specific steps:
(1) weighing euglena beta-1, 3-glucan, composite active alkaloid, deep sea fish peptide, micromolecular potassium hyaluronate (the molecular weight is less than 3000), D-aminoglucosone glutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to the parts by weight;
(2) and (2) uniformly mixing the components in the step (1).
CN202011300901.4A 2020-11-19 2020-11-19 Pharmaceutical composition for treating gout and preparation method thereof Active CN112138138B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011300901.4A CN112138138B (en) 2020-11-19 2020-11-19 Pharmaceutical composition for treating gout and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011300901.4A CN112138138B (en) 2020-11-19 2020-11-19 Pharmaceutical composition for treating gout and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112138138A true CN112138138A (en) 2020-12-29
CN112138138B CN112138138B (en) 2023-05-23

Family

ID=73887447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011300901.4A Active CN112138138B (en) 2020-11-19 2020-11-19 Pharmaceutical composition for treating gout and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112138138B (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068718A1 (en) * 2000-10-03 2002-06-06 Pierce Scott W. Chondroprotective/restorative compositions and methods of use thereof
CN103920135A (en) * 2014-04-23 2014-07-16 青岛昆布生物工程有限公司 Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof
CN104621432A (en) * 2013-11-12 2015-05-20 江苏艾兰得营养品有限公司 Glucosamine composite tablets and preparation method thereof
CN104645332A (en) * 2015-03-06 2015-05-27 江苏正大清江制药有限公司 Pharmaceutical composition for relieving and preventing arthritis
CN105709207A (en) * 2016-01-29 2016-06-29 徐宝贞 Medicine for treating gout
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CN107660795A (en) * 2017-09-01 2018-02-06 武汉龙族药号生物医药科技有限公司 One kind prevention gout plaster taste and preparation method thereof
CN110946874A (en) * 2019-12-27 2020-04-03 华熙生物科技股份有限公司 Hyaluronic acid composition for relieving osteoarthritis
CN111513325A (en) * 2020-04-29 2020-08-11 私诺(北京)健康科技有限公司 Food for reducing uric acid
CN111732675A (en) * 2020-08-18 2020-10-02 山东华熙海御生物医药有限公司 Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068718A1 (en) * 2000-10-03 2002-06-06 Pierce Scott W. Chondroprotective/restorative compositions and methods of use thereof
CN104621432A (en) * 2013-11-12 2015-05-20 江苏艾兰得营养品有限公司 Glucosamine composite tablets and preparation method thereof
CN103920135A (en) * 2014-04-23 2014-07-16 青岛昆布生物工程有限公司 Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof
CN104645332A (en) * 2015-03-06 2015-05-27 江苏正大清江制药有限公司 Pharmaceutical composition for relieving and preventing arthritis
CN105709207A (en) * 2016-01-29 2016-06-29 徐宝贞 Medicine for treating gout
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
CN107660795A (en) * 2017-09-01 2018-02-06 武汉龙族药号生物医药科技有限公司 One kind prevention gout plaster taste and preparation method thereof
CN110946874A (en) * 2019-12-27 2020-04-03 华熙生物科技股份有限公司 Hyaluronic acid composition for relieving osteoarthritis
CN111513325A (en) * 2020-04-29 2020-08-11 私诺(北京)健康科技有限公司 Food for reducing uric acid
CN111732675A (en) * 2020-08-18 2020-10-02 山东华熙海御生物医药有限公司 Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李楠等: "《有机化学第2版》", 31 July 2017, 北京：中国农业大学出版社 *

Also Published As

Publication number Publication date
CN112138138B (en) 2023-05-23

Similar Documents

Publication Publication Date Title
Zulaikhah Health benefits of tender coconut water (TCW)
US20090142410A1 (en) Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise
CN112546052A (en) Composition containing marine oligosaccharide for preventing and treating gout
CN110420293A (en) The plant composition and plant composition solid particle for treating hyperuricemia and gout
CN112057605A (en) Marine collagen oligopeptide and preparation method thereof
CN111000973A (en) Composition with gout improving effect and application thereof
KR100594520B1 (en) Composition Comprising an Alpha-Amylase Inhibitor and At Least One Physiologically Acceptable Compound Capable of Reducing Intestinal Absorption of ?Fast Sugars?
CN112138138A (en) A pharmaceutical composition for treating gout and preparation method thereof
US20190000903A1 (en) Biopolymer compositions for the treatment and prevention of liver disease
EP1162937B1 (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
CN105193837B (en) A kind of creme and preparation method thereof of prevention and treatment joint disease
WO2006120974A1 (en) Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage
CN1739556A (en) Dietotherapeutic nutrient for preventing and treating secondary gout and its prepn process
CN111228459B (en) Composition for treating and preventing gout
McPherson et al. Cysteine: the fun-ke nutraceutical
CN108379455B (en) Uric acid reducing composition
Alubaidy Study the biochemical effect of gum arabic in liver injury and blood serum of mice induced by gentamicin
MXPA96005979A (en) Novedous use of gluten peptides as absorption stimulants of minerals and as preventive agents of hyperlipidemia and hypercolesterole
CN112933175A (en) Traditional Chinese medicine composition for treating gout
JPH0534341B2 (en)
CN111939179A (en) Application of cobra venom or extract thereof in preparation of medicine for reducing uric acid and/or resisting gouty arthritis
CN116370574B (en) Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof
CN111346102A (en) Application of baicalin in treating and preventing non-alcoholic fatty liver disease
CN116585379B (en) Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout
WO2023000263A1 (en) Use of brown algae oligosaccharide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant